Abstract
Tumour-specific antigens (TSA; ref. 1) have been exploited in the diagnosis2 and imaging3 of human cancer and anti-TSA antibodies have therapeutic potential4. Vaccination with TSA5–8 or anti-idiotypic (TSA) antibodies9,10 has also been used to control tumour growth in model systems. An effective immune response nevertheless demands copresentation of antigen with host histocompatibility determinants11. We therefore examined whether live vaccinia virus recombinants expressing TSA in cells of the vaccinated host might better elicit tumour immunity. Polyoma virus (PY) is tumorigenic in rodents; because killed PY-transformed cells can elicit tumour immunity, a PY-specific TSA has been postulated12–14. Tumorigenesis involves expression of three early PY proteins15‐17, large-T (LT), middle-T (MT) and small-T (ST), but their role as TSAs is unclear. We therefore expressed the three T proteins in separate vaccinia recombinants. Rejection of PY tumours was observed in rats immunized with recombinants expressing either LT or MT. Further, tumour-bearing animals could be induced to reject their tumours by inoculation of recombinants.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Hellström, K. E., Hellström, I. & Brown, J. P. Springer Semin. Immunopalh. 5, 127–146 (1982).
Herlyn, M., Blaszczyk, M. & Koprowski, H. Contr. Oncol. 19, 160–170 (1984).
Begent, R. H. J. Biochem. biophys. Acta 780, 151–166 (1985).
Miller, R. A. et al. Hybridomus in Cancer Diagnosis and Treatment (eds Mitchell, M. S. & Oettgen, H. F.) 133–140 (Raven, New York, 1982).
Gross, L. Cancer Res. 3, 326–333 (1943).
Foley, E. J. Cancer Res. 13, 835–837 (1953).
Prehn, R. T. & Main, J. M. J. natn. Cancer Inst. 18, 769–778 (1957).
Tevethia, S. S., Flyer, D. C. & Tijan, R. Virology 107, 13–23 (1980).
Lee, V. K. et al. Proc. natn. Acad. Sci. U.S.A. 82, 6286–6290 (1985).
Herlyn, D., Ross, A. H. & Koprowski, H. Science 232, 100–102 (1986).
Zinkernagel, R. M. & Doherty, P. C. Adv. Immun. 27, 51–177 (1979).
Sjogren, H. O., Hellström, I. & Klein, I. Cancer Res. 21, 329–337 (1961).
Habel, K. Proc. Soc. exp. Biol. Med. 106, 722–725 (1961).
Ito, Y., Brocklehurst, J. R. & Dulbecco, R. Proc. natn. Acad. Sci. U.S.A. 74, 4666–4670 (1977).
Basilico, C. Pharmac. Ther. 26, 235–272 (1984).
Griffin, B. E. & Dilworth, S. M. Adv. Cancer Res. 39, 183–268 (1983).
Tooze, J. DNA Tumor Viruses (Cold Spring Harbor Laboratory, New York, 1981).
Panicali, D. & Paoletti, E. Proc. natn. Acad. Sci. U.S.A. 79, 4927–4931 (1982).
Mackett, M., Smith, G. L. & Moss, B. Proc. natn. Acad. Sci. U.S.A. 79, 7415–7419 (1982).
Smith, G. L., Mackett, M. & Moss, B. Biolechnol. Genet. Engng. Reu. 2, 383–407 (1984).
Kieny, M. P. et al. Nature 312, 163–166 (1984).
Wiktor, T. J. et al. Proc. natn. Acad. Sci. U.S.A. 81, 7194–7198 (1984).
Wiktor, T. J., Kieny, M. P. & Lathe, R. Appl. Virol. Res. (in the press).
Bennink, J. R., Yewdell, J. W., Smith, G. L., Moller, C. & Moss, B. Nature 311, 578–579 (1984).
McMichael, A. J., Michie, C. A., Gotch, F. M., Smith, G. L. & Moss, B. J. gen. Virol 67, 719–726 (1986).
Hellström, K. E. & Hellström, I. Adv. Cancer Res. 12, 167–223 (1969).
Heberman, R. B. Adv. Cancer Res. 19, 207–263 (1974).
Treisraan, R., Novak, U., Favaloro, J. & Kamen, R. Nature 292, 595–600 (1981).
Rassoulzadegan, M. et al. Nature 300, 713–718 (1982).
Takemoto, K. K., Malmgren, R. A. & Habel, K. Virology 28, 485–488 (1966).
Zhu, Z. et al. J. Virol. 51, 170–180 (1984).
Dilworth, S. M. et al. EMBO J. 5, 491–499 (1986).
Schaffhausen, B. S., Dorai, H., Arakere, G. & Benjamin, T. L. Molec. cell. Biol. 2, 1187–1198 (1982).
Old, L. J., Clarke, D. A. & Benacerraf, B. Nature 184, 291–292 (1959).
Koprowski, H. & Norton, T. W. Cancer 3, 874–885 (1950).
Froscher, B. G. & Klinman, N. R. J. exp. Med. 164, 196–210 (1986).
Dalianis, T., Ramqvist, T. & Klein, G. Int. J. Cancer 34, 403–406 (1984).
Sharma, S., Rodgers, L., Brandsma, J., Gething, M. J. & Sambrook, J. EMBO J. 4, 1479–1489 (1985).
Bennink, J. R., Yewdell, J. W. & Gerhard, W. Nature 296, 75–76 (1982).
Townsend, A. R. M., McMichael, A. J., Carter, N. P., Haddleston, J. A. & Brownlee, G. G. Cell 39, 13–25 (1984).
Yewdell, J. W., Bennink, J. R., Smith, G. L. & Moss, B. Proc. natn. Acad. Sci. U.S.A. 82, 1785–1789 (1985).
Koprowski, H., Herlyn, M., Steplewski, Z. & Sears, H. F. Science 212, 53–56 (1981).
Real, F. X. et al. J. exp. Med. 160, 1219–1233 (1984).
Ueda, R. et al. J. exp. Med. 150, 564–572 (1979).
Drebin, J. A., Stern, D. F., Link, V. C., Weinberg, R. A. & Greene, M. I. Nature 312, 545–548 (1984).
Peto, R. & Zur Hausen, H. (eds) Banbury Report 21, Viral Etiology of Cervical Cancer (Cold Spring Harbor Laboratory, New York, 1986).
Kieny, M. P. et al. Biol Technology 4, 790–795 (1986).
Clertant, P., Gaudray, P., May, E. & Cuzin, F. J. biol. Chem. 259, 15196–15293 (1984).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lathe, R., Kieny, M., Gerlinger, P. et al. Tumour prevention and rejection with recombinant vaccinia. Nature 326, 878–880 (1987). https://doi.org/10.1038/326878a0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/326878a0
This article is cited by
-
Inhibition of tumor growth by recombinant vaccinia virus expressing GA733/CO17-1A/EpCAM/KSA/KS1-4 antigen in mice
Cancer Gene Therapy (2002)
-
Cancer vaccines
Nature Medicine (1998)
-
Papillomavirus Vaccines
Clinical Immunotherapeutics (1994)
-
The live vector approach—viruses
World Journal of Microbiology and Biotechnology (1991)
-
Role of major histocompatibility complex class-I molecules in tumor rejection
Immunologic Research (1990)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.